Severine Vermeire, Gert Van Assche, Paul Rutgeerts
{"title":"炎症性肠病的疫苗接种和感染预防。","authors":"Severine Vermeire, Gert Van Assche, Paul Rutgeerts","doi":"10.3410/M2-80","DOIUrl":null,"url":null,"abstract":"<p><p>The current medical therapy used in Crohn's disease and ulcerative colitis comprises drugs that interfere with immune response and therefore caution is needed for infectious side effects, and where possible, strategies to prevent their occurrence should be undertaken. Last year, international consensus guidelines on this topic were published by the European Crohn's and Colitis Organisation.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"2 ","pages":"80"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/db/medrep-02-80.PMC2998810.pdf","citationCount":"6","resultStr":"{\"title\":\"Vaccination and infection prevention in inflammatory bowel disease.\",\"authors\":\"Severine Vermeire, Gert Van Assche, Paul Rutgeerts\",\"doi\":\"10.3410/M2-80\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The current medical therapy used in Crohn's disease and ulcerative colitis comprises drugs that interfere with immune response and therefore caution is needed for infectious side effects, and where possible, strategies to prevent their occurrence should be undertaken. Last year, international consensus guidelines on this topic were published by the European Crohn's and Colitis Organisation.</p>\",\"PeriodicalId\":88480,\"journal\":{\"name\":\"F1000 medicine reports\",\"volume\":\"2 \",\"pages\":\"80\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/db/medrep-02-80.PMC2998810.pdf\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"F1000 medicine reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3410/M2-80\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000 medicine reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3410/M2-80","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Vaccination and infection prevention in inflammatory bowel disease.
The current medical therapy used in Crohn's disease and ulcerative colitis comprises drugs that interfere with immune response and therefore caution is needed for infectious side effects, and where possible, strategies to prevent their occurrence should be undertaken. Last year, international consensus guidelines on this topic were published by the European Crohn's and Colitis Organisation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
